BMS-986340
- Generic Name
- BMS-986340
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Gastric/Gastroesophageal Junction AdenocarcinomaCarcinoma, Renal CellCervical CancerNon-Small-Cell Lung CancerUrothelial CarcinomaOvarian NeoplasmsMicrosatellite Stable Colorectal CancerSquamous Cell Carcinoma of Head and NeckTriple Negative Breast NeoplasmsPancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 905
- Registration Number
- NCT04895709
- Locations
- 🇩🇪
Universitaetsklinikum Essen, Essen, Germany
🇺🇸Community Cancer Institute, Clovis, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath